CN109414438A - 用于治疗癌症的组合物和方法 - Google Patents

用于治疗癌症的组合物和方法 Download PDF

Info

Publication number
CN109414438A
CN109414438A CN201780037213.3A CN201780037213A CN109414438A CN 109414438 A CN109414438 A CN 109414438A CN 201780037213 A CN201780037213 A CN 201780037213A CN 109414438 A CN109414438 A CN 109414438A
Authority
CN
China
Prior art keywords
cancer
formula
pharmaceutically acceptable
compounds
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780037213.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·坎杜拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saierlikesi Biological Pte Ltd
Original Assignee
Saierlikesi Biological Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saierlikesi Biological Pte Ltd filed Critical Saierlikesi Biological Pte Ltd
Publication of CN109414438A publication Critical patent/CN109414438A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780037213.3A 2016-06-28 2017-05-12 用于治疗癌症的组合物和方法 Pending CN109414438A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN201641022026 2016-06-28
IN201641022026 2016-06-28
IN201641025259 2016-07-22
IN201641025259 2016-07-22
IN201741006185 2017-02-21
IN201741006185 2017-02-21
PCT/IB2017/052814 WO2018002739A1 (en) 2016-06-28 2017-05-12 Compositions and methods for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN109414438A true CN109414438A (zh) 2019-03-01

Family

ID=60785109

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780037213.3A Pending CN109414438A (zh) 2016-06-28 2017-05-12 用于治疗癌症的组合物和方法

Country Status (14)

Country Link
US (2) US10858349B2 (https=)
EP (1) EP3452044A4 (https=)
JP (1) JP6950972B2 (https=)
KR (1) KR102306412B1 (https=)
CN (1) CN109414438A (https=)
AU (3) AU2017286852B2 (https=)
BR (1) BR112018076257A2 (https=)
CA (1) CA3027118C (https=)
IL (2) IL263563A (https=)
MX (1) MX384144B (https=)
RU (1) RU2770081C2 (https=)
SG (1) SG11201810947PA (https=)
WO (1) WO2018002739A1 (https=)
ZA (1) ZA201808232B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210171564A1 (en) * 2018-08-03 2021-06-10 Cellix Bio Provate Limited Compositions and methods for the treatment of cancer
EP3679952A1 (en) * 2019-01-10 2020-07-15 Université de Strasbourg Nanoemulsions encapsulating prodrugs
US20250186435A1 (en) * 2020-05-19 2025-06-12 Cellix Bio Private Limited Pharmaceutical formulations and their preparations for treatment of cancer
WO2022043902A1 (en) * 2020-08-29 2022-03-03 Cellix Bio Private Limited Process for the preparation of derivatives of 5-fluoro pyrimidines used as anti cancer agents
WO2022049462A1 (en) * 2020-09-05 2022-03-10 Cellix Bio Private Limited Process for the preparation of derivatives of 5-fluoro pyrimidines used as anti cancer agents

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966891A (en) * 1987-11-17 1990-10-30 Hoffmann-La Roche Inc. Fluorocytidine derivatives
EP0602478A1 (en) * 1992-12-18 1994-06-22 F. Hoffmann-La Roche Ag Novel process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO2002011668A2 (en) * 2000-08-09 2002-02-14 Kolon Industries, Inc. 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients
WO2010063080A1 (en) * 2008-12-05 2010-06-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1192386A (ja) * 1997-09-17 1999-04-06 Nikken Chem Co Ltd ５−フルオロウリジン誘導体を有効成分とする抗癌剤
CN102215691B (zh) 2008-08-01 2015-02-04 陶氏益农公司 5-氟胞嘧啶作为杀真菌剂的用途
WO2015116782A1 (en) 2014-01-29 2015-08-06 Board Of Regents, The University Of Texas System Nucleobase analogue derivatives and their applications
GB201419015D0 (en) * 2014-10-24 2014-12-10 Orca Pharmaceuticals Ltd Compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US4966891A (en) * 1987-11-17 1990-10-30 Hoffmann-La Roche Inc. Fluorocytidine derivatives
EP0602478A1 (en) * 1992-12-18 1994-06-22 F. Hoffmann-La Roche Ag Novel process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
WO2002011668A2 (en) * 2000-08-09 2002-02-14 Kolon Industries, Inc. 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients
WO2010063080A1 (en) * 2008-12-05 2010-06-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ENDO，HIROTAKA等: "Lymphatic delivery of anticancer drug by lipid microspheres containing prodrug of 5"-deoxy-5 fluorouridine", 《DRUG DELIVERY SYSTEM》 *
NOBUO SHIMMA等: "The Design and Synthesis of a New Tumor-Selective Fluoropyrimidine Carbamate, Capecitabine", 《BIOORGANIC & MEDICINAL CHEMISTRY》 *
R.B.DIASIO: "Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans:possible factor in 5-fluorocytosine clinical toxicity", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 *
V. JHANSI RANI等: "Synthesis and biological activity evaluation of cytidine-50-deoxy-5-fluoro-N-[(alkoxy/aryloxy)] carbonyl-cyclic 20,30-carbonates", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *

Also Published As

Publication number Publication date
CA3027118C (en) 2023-08-15
JP6950972B2 (ja) 2021-10-20
MX2019000279A (es) 2019-08-01
US20210078983A1 (en) 2021-03-18
RU2770081C2 (ru) 2022-04-14
IL280587A (en) 2021-03-25
IL280587B (en) 2021-10-31
ZA201808232B (en) 2019-09-25
SG11201810947PA (en) 2019-01-30
US20190292171A1 (en) 2019-09-26
AU2017286852A1 (en) 2019-01-17
NZ749512A (en) 2021-08-27
KR20190034539A (ko) 2019-04-02
CA3027118A1 (en) 2018-01-04
EP3452044A1 (en) 2019-03-13
EP3452044A4 (en) 2020-04-22
JP2019519563A (ja) 2019-07-11
MX384144B (es) 2025-03-14
AU2021203748A1 (en) 2021-07-08
AU2023208158A1 (en) 2023-08-17
WO2018002739A1 (en) 2018-01-04
RU2019100713A3 (https=) 2021-02-08
AU2017286852B2 (en) 2021-05-06
RU2019100713A (ru) 2020-07-28
KR102306412B1 (ko) 2021-09-28
US10858349B2 (en) 2020-12-08
BR112018076257A2 (pt) 2019-03-26
IL263563A (en) 2019-01-31

Similar Documents

Publication Publication Date Title
WO2013024376A1 (en) Compositions and methods for the treatment of atherothrombosis
US20210078983A1 (en) Compositions and methods for the treatment of cancer
WO2016046675A1 (en) Compositions and methods for the treatment of neurological diseases
US20210171564A1 (en) Compositions and methods for the treatment of cancer
US9475747B1 (en) Compositions and methods for the treatment of urea cycle disorders and gout
WO2017090007A1 (en) Compositions and methods for the treatment of urea cycle disorders and hepatic diseases
WO2017221083A1 (en) Compositions and methods for the treatment of viral infections
CN107108535B (zh) 用于治疗多发性硬化的富马酸单甲酯与哌嗪或乙二胺的三组分盐
JP2020055837A (ja) 多発性硬化症の治療のための組成物及び方法
NZ749512B2 (en) Compositions and methods for the treatment of cancer
US9206111B1 (en) Compositions and methods for the treatment of neurological diseases
WO2016203352A2 (en) Compositions and methods for the treatment of cancer
WO2016067297A1 (en) Salts of valproic acid with piperazine, ethylenediamine, lysine and/or eicosapentaenoic ecid (epa) amine derivatives for the treatment of epilepsy
WO2016046670A1 (en) Compositions and methods for the treatment of renal diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190301